The Experts below are selected from a list of 4542 Experts worldwide ranked by ideXlab platform

Torsten Haferlach - One of the best experts on this subject based on the ideXlab platform.

  • acute monoblastic Monocytic Leukemia and chronic myeloMonocytic Leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells
    Leukemia & Lymphoma, 2011
    Co-Authors: Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Ulrike Bacher, Torsten Haferlach
    Abstract:

    Differentiation between acute monoblastic/Monocytic Leukemia (AMoL) and chronic myeloMonocytic Leukemia (CMML) can be difficult. Therefore, we compared immunophenotypes between 27 cases of AMoL and 138 cases of CMML. Monocytopoietic cells showed aberrant coexpression of CD56 in all cases of AMoL vs. 81.9% of CMML (p = 0.015). No other aberrantly expressed antigen was found in AMoL, while in CMML CD2 coexpression was found in 21.7% (p = 0.005), lack of CD13 in 10.9%, and of HLA-DR in 4.3% (NS). Cytomorphology identified higher blast percentages and lower percentages of monocytes and granulocytic cells in AMoL (p <0.001). Multiparameter flow-cytometry (MFC) found higher percentages of blasts (17.6 ± 25.2 vs. 4.1 ± 3.2, p <0.001) and monocytopoietic cells (29.1 ± 27.5 vs. 19.9 ± 12.2, p = 0.012) in AMoL and more granulocytic cells in CMML (52.4 ± 19.2 vs. 26.0 ± 22.4, p <0.001). The mean ratio of Monocytic:granulocytic cells was higher in AMoL (5.0 vs. 0.8; p <0.001). It can be concluded that AMoL and CMML d...

  • acute monoblastic Monocytic Leukemia and chronic myeloMonocytic Leukemia share common immunophenotypic features but differ in the extend of aberrantly expressed antigens and the amount of granulocytic cells
    Blood, 2009
    Co-Authors: Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach
    Abstract:

    Abstract 3799 Poster Board III-735 Acute monoblastic/Monocytic Leukemia (AMoL) is grouped into acute myeloid Leukemia and related neoplasms by the 2008 WHO classification while chronic myeloMonocytic Leukemia (CMML) in grouped into myelodysplastic/myeloproliferative neoplasms (MDS/MPN). However, both entities share common features and sometimes may be difficult to differentiate from each other. In particular, monopoietic cells can be easily identified by multiparameter flow cytometry (MFC) based on their CD45/side-scatter (SSC) signal. However, immunophenotypes of monoblasts and dysplastic monocytes largely overlap. Their differentiation from each other is better accomplished by cytomorphology (CM) and the use of non-specific esterase. We compared cytomorphologic, immunophenotypic and cytogenetic results between 26 patients with AMoL and 139 patients with CMML which were analyzed at diagnosis between 2005 and 2009 in order to identify shared and discriminative characteristics. In AMoL vs. CMML 65.4% vs. 73.4% were male, the median age was 65.4 vs. 72.5 years (range 19.3-82.0 vs. 21.9-87.9 years, p Disclosures: Kern:MLL Munich Leukemia Laboratory: Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership. Schnittger:MLL Munich Leukemia Laboratory: Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership.

Wolfgang Kern - One of the best experts on this subject based on the ideXlab platform.

  • acute monoblastic Monocytic Leukemia and chronic myeloMonocytic Leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells
    Leukemia & Lymphoma, 2011
    Co-Authors: Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Ulrike Bacher, Torsten Haferlach
    Abstract:

    Differentiation between acute monoblastic/Monocytic Leukemia (AMoL) and chronic myeloMonocytic Leukemia (CMML) can be difficult. Therefore, we compared immunophenotypes between 27 cases of AMoL and 138 cases of CMML. Monocytopoietic cells showed aberrant coexpression of CD56 in all cases of AMoL vs. 81.9% of CMML (p = 0.015). No other aberrantly expressed antigen was found in AMoL, while in CMML CD2 coexpression was found in 21.7% (p = 0.005), lack of CD13 in 10.9%, and of HLA-DR in 4.3% (NS). Cytomorphology identified higher blast percentages and lower percentages of monocytes and granulocytic cells in AMoL (p <0.001). Multiparameter flow-cytometry (MFC) found higher percentages of blasts (17.6 ± 25.2 vs. 4.1 ± 3.2, p <0.001) and monocytopoietic cells (29.1 ± 27.5 vs. 19.9 ± 12.2, p = 0.012) in AMoL and more granulocytic cells in CMML (52.4 ± 19.2 vs. 26.0 ± 22.4, p <0.001). The mean ratio of Monocytic:granulocytic cells was higher in AMoL (5.0 vs. 0.8; p <0.001). It can be concluded that AMoL and CMML d...

  • acute monoblastic Monocytic Leukemia and chronic myeloMonocytic Leukemia share common immunophenotypic features but differ in the extend of aberrantly expressed antigens and the amount of granulocytic cells
    Blood, 2009
    Co-Authors: Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach
    Abstract:

    Abstract 3799 Poster Board III-735 Acute monoblastic/Monocytic Leukemia (AMoL) is grouped into acute myeloid Leukemia and related neoplasms by the 2008 WHO classification while chronic myeloMonocytic Leukemia (CMML) in grouped into myelodysplastic/myeloproliferative neoplasms (MDS/MPN). However, both entities share common features and sometimes may be difficult to differentiate from each other. In particular, monopoietic cells can be easily identified by multiparameter flow cytometry (MFC) based on their CD45/side-scatter (SSC) signal. However, immunophenotypes of monoblasts and dysplastic monocytes largely overlap. Their differentiation from each other is better accomplished by cytomorphology (CM) and the use of non-specific esterase. We compared cytomorphologic, immunophenotypic and cytogenetic results between 26 patients with AMoL and 139 patients with CMML which were analyzed at diagnosis between 2005 and 2009 in order to identify shared and discriminative characteristics. In AMoL vs. CMML 65.4% vs. 73.4% were male, the median age was 65.4 vs. 72.5 years (range 19.3-82.0 vs. 21.9-87.9 years, p Disclosures: Kern:MLL Munich Leukemia Laboratory: Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership. Schnittger:MLL Munich Leukemia Laboratory: Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership.

Claudia Haferlach - One of the best experts on this subject based on the ideXlab platform.

  • acute monoblastic Monocytic Leukemia and chronic myeloMonocytic Leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells
    Leukemia & Lymphoma, 2011
    Co-Authors: Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Ulrike Bacher, Torsten Haferlach
    Abstract:

    Differentiation between acute monoblastic/Monocytic Leukemia (AMoL) and chronic myeloMonocytic Leukemia (CMML) can be difficult. Therefore, we compared immunophenotypes between 27 cases of AMoL and 138 cases of CMML. Monocytopoietic cells showed aberrant coexpression of CD56 in all cases of AMoL vs. 81.9% of CMML (p = 0.015). No other aberrantly expressed antigen was found in AMoL, while in CMML CD2 coexpression was found in 21.7% (p = 0.005), lack of CD13 in 10.9%, and of HLA-DR in 4.3% (NS). Cytomorphology identified higher blast percentages and lower percentages of monocytes and granulocytic cells in AMoL (p <0.001). Multiparameter flow-cytometry (MFC) found higher percentages of blasts (17.6 ± 25.2 vs. 4.1 ± 3.2, p <0.001) and monocytopoietic cells (29.1 ± 27.5 vs. 19.9 ± 12.2, p = 0.012) in AMoL and more granulocytic cells in CMML (52.4 ± 19.2 vs. 26.0 ± 22.4, p <0.001). The mean ratio of Monocytic:granulocytic cells was higher in AMoL (5.0 vs. 0.8; p <0.001). It can be concluded that AMoL and CMML d...

  • acute monoblastic Monocytic Leukemia and chronic myeloMonocytic Leukemia share common immunophenotypic features but differ in the extend of aberrantly expressed antigens and the amount of granulocytic cells
    Blood, 2009
    Co-Authors: Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach
    Abstract:

    Abstract 3799 Poster Board III-735 Acute monoblastic/Monocytic Leukemia (AMoL) is grouped into acute myeloid Leukemia and related neoplasms by the 2008 WHO classification while chronic myeloMonocytic Leukemia (CMML) in grouped into myelodysplastic/myeloproliferative neoplasms (MDS/MPN). However, both entities share common features and sometimes may be difficult to differentiate from each other. In particular, monopoietic cells can be easily identified by multiparameter flow cytometry (MFC) based on their CD45/side-scatter (SSC) signal. However, immunophenotypes of monoblasts and dysplastic monocytes largely overlap. Their differentiation from each other is better accomplished by cytomorphology (CM) and the use of non-specific esterase. We compared cytomorphologic, immunophenotypic and cytogenetic results between 26 patients with AMoL and 139 patients with CMML which were analyzed at diagnosis between 2005 and 2009 in order to identify shared and discriminative characteristics. In AMoL vs. CMML 65.4% vs. 73.4% were male, the median age was 65.4 vs. 72.5 years (range 19.3-82.0 vs. 21.9-87.9 years, p Disclosures: Kern:MLL Munich Leukemia Laboratory: Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership. Schnittger:MLL Munich Leukemia Laboratory: Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership.

Susanne Schnittger - One of the best experts on this subject based on the ideXlab platform.

  • acute monoblastic Monocytic Leukemia and chronic myeloMonocytic Leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells
    Leukemia & Lymphoma, 2011
    Co-Authors: Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Ulrike Bacher, Torsten Haferlach
    Abstract:

    Differentiation between acute monoblastic/Monocytic Leukemia (AMoL) and chronic myeloMonocytic Leukemia (CMML) can be difficult. Therefore, we compared immunophenotypes between 27 cases of AMoL and 138 cases of CMML. Monocytopoietic cells showed aberrant coexpression of CD56 in all cases of AMoL vs. 81.9% of CMML (p = 0.015). No other aberrantly expressed antigen was found in AMoL, while in CMML CD2 coexpression was found in 21.7% (p = 0.005), lack of CD13 in 10.9%, and of HLA-DR in 4.3% (NS). Cytomorphology identified higher blast percentages and lower percentages of monocytes and granulocytic cells in AMoL (p <0.001). Multiparameter flow-cytometry (MFC) found higher percentages of blasts (17.6 ± 25.2 vs. 4.1 ± 3.2, p <0.001) and monocytopoietic cells (29.1 ± 27.5 vs. 19.9 ± 12.2, p = 0.012) in AMoL and more granulocytic cells in CMML (52.4 ± 19.2 vs. 26.0 ± 22.4, p <0.001). The mean ratio of Monocytic:granulocytic cells was higher in AMoL (5.0 vs. 0.8; p <0.001). It can be concluded that AMoL and CMML d...

  • acute monoblastic Monocytic Leukemia and chronic myeloMonocytic Leukemia share common immunophenotypic features but differ in the extend of aberrantly expressed antigens and the amount of granulocytic cells
    Blood, 2009
    Co-Authors: Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach
    Abstract:

    Abstract 3799 Poster Board III-735 Acute monoblastic/Monocytic Leukemia (AMoL) is grouped into acute myeloid Leukemia and related neoplasms by the 2008 WHO classification while chronic myeloMonocytic Leukemia (CMML) in grouped into myelodysplastic/myeloproliferative neoplasms (MDS/MPN). However, both entities share common features and sometimes may be difficult to differentiate from each other. In particular, monopoietic cells can be easily identified by multiparameter flow cytometry (MFC) based on their CD45/side-scatter (SSC) signal. However, immunophenotypes of monoblasts and dysplastic monocytes largely overlap. Their differentiation from each other is better accomplished by cytomorphology (CM) and the use of non-specific esterase. We compared cytomorphologic, immunophenotypic and cytogenetic results between 26 patients with AMoL and 139 patients with CMML which were analyzed at diagnosis between 2005 and 2009 in order to identify shared and discriminative characteristics. In AMoL vs. CMML 65.4% vs. 73.4% were male, the median age was 65.4 vs. 72.5 years (range 19.3-82.0 vs. 21.9-87.9 years, p Disclosures: Kern:MLL Munich Leukemia Laboratory: Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership. Schnittger:MLL Munich Leukemia Laboratory: Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership.

Saleh Daoud - One of the best experts on this subject based on the ideXlab platform.

  • aleukemic Monocytic Leukemia cutis
    Mayo Clinic proceedings, 1996
    Co-Authors: Mazen S Daoud, John L Snow, Lawrence E Gibson, Saleh Daoud
    Abstract:

    Aleukemic Leukemia cutis is a rare condition in which leukemic cells invade the skin before they appear in peripheral blood or bone marrow specimens. Herein we describe a 67-year-old man who underwent assessment because of papules and nodules on his back and lower extremities. A biopsy of these lesions confirmed a dense, predominantly Monocytic infiltrate of the dermis and subcutaneous tissue. Immunohistochemical stains were positive for CD43 (Leu-22) as well as Monocytic markers. Bone marrow and peripheral blood examinations failed to reveal Leukemia. Treatment was based on the results of the skin biopsy, and the patient is doing weill year after therapy.